

This is a repository copy of *Electronic personal assessment questionnaire for vascular patients (ePAQ-VAS): development and validity.*

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/159201/

Version: Supplemental Material

Article:

Aber, A., Phillips, P., Hughes, J. et al. (7 more authors) (2020) Electronic personal assessment questionnaire for vascular patients (ePAQ-VAS): development and validity. British Journal of Surgery, 107 (8). pp. 1004-1012. ISSN 0007-1323

https://doi.org/10.1002/bjs.11531

This is the peer reviewed version of the following article: Aber, A., Phillips, P., Hughes, J., Keetharuth, A.D., Rooney, G., Radley, S., Walters, S., Nawaz, S., Jones, G. and Michaels, J. (2020), Electronic personal assessment questionnaire for vascular conditions (ePAQ-VAS): development and validity. Br J Surg., which has been published in final form at https://doi.org/10.1002/bjs.11531. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Table 1: Number of respondents and mean score for each scale of ePAQ-VAS

Scale	Number of	Mean score	Standard deviation
	respondents	(out of 100)	
AAA related anxiety	121	23.74	21.84
AAA impact on ADL	121	17.41	20.82
CAD related anxiety	50	44.17	29.61
CAD impact on ADL	50	32.40	30.29
PAD Symptoms	308	47.08	26.86
PAD impact on ADL	308	50.28	30.88
VLU symptoms	122	34.97	24.37
VLU impact on ADL	122	55.46	30.91
VVs symptoms	248	36.86	18.91
VV impact on ADL	248	28.52	26.69

PAD impact on ADL, VLU impact on ADL and VVs impact on ADL was measured by the lower limb vascular disease impact on ADL scale in ePAQ-VAS